Announcements Trials
Browse Landscape

Phase

Phase 2 18Phase 3 7Phase NA 3Phase EARLY_PHASE1 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1CNS 1

Conditions

Neurotoxicity Syndromes 1Lymphoma 1Central Nervous System Neoplasms 1

Interventions

Rituximab 5fludarabine 4Cyclophosphamide 4pembrolizumab 2Bendamustine Hydrochloride 268Ga-pentixafor 2venetoclax 1pegylated granulocyte colony-stimulating factor, human 1pegfilgrastim 1motexafin gadolinium 1ibrutinib 1fludarabine phosphate 1daratumumab 1brexucabtagene autoleucel 1acalabrutinib 1Vincristine 1Valproic Acid 1Transplantation 1Tablets 1Surveys and Questionnaires 1Sugars 1Stem Cell Transplantation 1Simvastatin 1Roflumilast 1Ribavirin 1Radiotherapy 1Procarbazine 1Positron-Emission Tomography 1Pemetrexed 1Nivolumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Lymphoma × Procarbazine × Clear all
NCT00734773 2012-05-18

Pilot Study of MGd + High-dose MTX-Based Chemoimmunotherapy + RT for Newly Dx PCNSL

Northwestern University

Phase EARLY_PHASE1 Withdrawn
CNSLymphoid

Lymphoma, Central Nervous System Neoplasms, Neurotoxicity Syndromes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡